Propanc Biopharma Inc (PPCBD) Q2 2025 Earnings Report

Revenue: No recognized revenue reported for QQ2 2025 in the disclosed figures (reported quarterly data shows 4,332 in cost of revenue, implying negligible gross profit). Operating income: -213,382 for QQ2 2025, an improvement in the absolute loss versus the prior year quarter but still a large negative figure. Net income: -430,183 for QQ2 2025, down versus the prior year quarter but showing a YoY improvement of ~26.3%. EPS: -32.23 for QQ2 2025, reflecting the heavy equity base and a continued loss position. Balance sheet and cash flow metrics indicate severe liquidity and leverage issues: cash and cash equivalents of 14,633; total current liabilities of 4,154,964; total assets 78,533; total liabilities 4,237,292; negative stockholders’ equity of -4,158,759; net debt of 1,194,398. Current ratio: 0.00433; quick ratio: 0.00433; cash ratio: 0.00352, signaling a precarious short‑term liquidity scenario.